PIKCel – developing inhalation technology in asthma and COPD treatment

The objective of the project is to confirm the therapeutic effect of the PI3K inhibitor in patients with lung diseases such as asthma or chronic obstructive pulmonary disease (COPD). The planned route of administration of the drug is inhalation. The project involves actions taken in four stages, including preclinical and toxicological studies, drug formulation, as well as phase I and II clinical trials.

The total value of the PIKCel project is PLN 23,508,985.88, of which PLN 15,373,271.42 will be received by the company under the Smart Growth Operational Programme.